Comparative outcomes of thromboprophylaxis between low molecular weight heparin (LMWH) and rivaroxaban in surgical gastrointestinal cancer patients
Not Applicable
- Conditions
- rivaroxaban ,thromboprophylaxisthromboprophylaxis ,surgical ,cancer
- Registration Number
- TCTR20190712003
- Lead Sponsor
- Ramathibodi hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 760
Inclusion Criteria
age > 18 years
gastrointestinal cancer
surgery
Exclusion Criteria
previous venous thromboembolism
Preoperative DVT
Coadministration of anticoagulant medication
rivaroxaban drug allergy
active clinical bleeding
poor renal function (GFR < 30)
impair liver function (Child-Pugh B and C)
History of heparin induced thrombocytopenia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Venous thromboembolism 1 month Ultrasound
- Secondary Outcome Measures
Name Time Method bleeding complication 1 month clinical diagnosis,cost-effectiveness 1 month cost of treatment,satisfaction scores 1 month record form